Marker Therapeutics, a clinical-stage immuno-oncology company, reported in its Q1 2026 filing continued advancement of its MAR-T cell therapy candidates for cancer treatment. The company remains pre-revenue and expects to incur losses over the coming years, projecting sufficient cash runway into the first quarter of 2027 assuming no additional grant income. Its proprietary technology aims to selectively amplify natural tumor-targeting T cells without genetic modification, targeting tumor heterogeneity in both hematologic and solid cancers. Funding constraints and regulatory hurdles remain key risks amid intensifying competition from established CAR-T therapies.